PetVivo Holdings, Inc. Achieves National Distribution of Spryng to More than 450 Veterinary Clinics
20 July 2023 - 10:20PM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company")
an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals and animal athletes is fastly approaching a
remarkable milestone – the sale of its signature product Spryng™
with OsteoCushion™ to its 500th veterinary clinic. PetVivo has
supplied this life enhancing product for companion animals to more
than 450 clinics in 47 states.
"We are rapidly approaching the elite status of
distribution of our life changing product, Spryng with OsteoCushion
Technology, to 500 clinics," said John Lai, Chief Executive Officer
of PetVivo Holdings, Inc. "This accomplishment reflects the
strength of our therapeutic medical device and the relentless
dedication of our amazing team of business development
representatives and experienced group of business and scientific
professionals. Most importantly, our growth is fueled by the rising
number of companion animals and their owners we serve, which
demonstrates our increasing presence across the country. With our
steady emergence in the market, Spryng is gaining national
recognition, and we expect to continue to drive accelerated growth
momentum."
SPRYNG™ with OsteoCushion™ Technology, is an
intra-articular injectable veterinary medical device consisting of
sterilized, extra-cellular matrix microparticles; Spryng
microparticles perform in the joint as wet, slippery micro-cushions
used in the management of lameness and other joint related
afflictions, such as osteoarthritis.
For more information about PetVivo Holdings,
Inc. and its innovative product, Spryng, please contact
info1@petvivo.com or visit https://petvivo.com/ and
https://sprynghealth.com/.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is currently
available for commercial sale to veterinarians.
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email:
info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2023 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Apr 2024 to May 2024
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From May 2023 to May 2024